Seres Therapeutics to Present at Two Upcoming May Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. NVDA
4. GNK
5. PLUR

6. USO
7. AZN
8. SPCX
9. FNGR
10. AGPU

Get Alerts MCRB Hot Sheet

Price: $4.51 -0.66%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced it will attend each of the following upcoming healthcare conferences:

Deutsche Bank 43rd Annual Health Care Conference: The company will participate in 1x1 meetings on Wednesday, May 9 in Boston, Mass.
Bank of America Merrill Lynch 2018 Health Care Conference: The company will present a corporate overview on Thursday, May 17 at 8:55 a.m. PT in Las Vegas, Nev.

A live audio webcast of the Bank of America Merrill Lynch presentation will be available under the “Investors and Media” section of Seres’ website. A replay will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.